CHF
MCID: CNG034
MIFTS: 70

Congestive Heart Failure (CHF)

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Congestive Heart Failure

MalaCards integrated aliases for Congestive Heart Failure:

Name: Congestive Heart Failure 12 74 29 6 15 37 17 71 32
Heart Failure 43 71
Cardiac Failure Congestive 12
Congestive Heart Disease 12
Heart Failure Congestive 54
Weak Heart 12
Chf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6000
ICD9CM 34 428 428.0 428.9
MeSH 43 D006333
NCIt 49 C3080 C50577
SNOMED-CT 67 42343007 84114007
ICD10 32 I50 I50.0 I50.9
UMLS 71 C0018801 C0018802

Summaries for Congestive Heart Failure

Disease Ontology : 12 A heart disease that is characterized by any structural or functional cardiac disorder that impairs the ability of the heart to fill with or pump a sufficient amount of blood throughout the body.

MalaCards based summary : Congestive Heart Failure, also known as heart failure, is related to pulmonary edema and orthostatic intolerance, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Congestive Heart Failure is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Cardiac conduction and Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases. The drugs Amiloride and Tamsulosin have been mentioned in the context of this disorder. Affiliated tissues include Adipose and Lateral Plate Mesoderm, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Heart failure (HF), also known as congestive heart failure (CHF) and congestive cardiac failure (CCF),... more...

Related Diseases for Congestive Heart Failure

Diseases related to Congestive Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1404)
# Related Disease Score Top Affiliating Genes
1 pulmonary edema 33.4 REN NPPB NPPA EDN1 AGTR1 ACE
2 orthostatic intolerance 33.4 EDN1 AGTR1 ADRB1 ADRA2C ACE
3 peripartum cardiomyopathy 33.4 TTN MYH7 ADRB1 ACE
4 cardiac arrest 33.3 TTN REN NPPB MYH7 MYH6 ACE
5 hypertensive heart disease 32.9 REN NPPB NPPA AGTR1 ACE
6 twin-to-twin transfusion syndrome 32.6 REN NPPA AGTR1
7 heart disease 32.5 TTN REN NPPC NPPB NPPA MYH7
8 mitral valve insufficiency 32.4 REN NPPB NPPA MYH7 MYH6 ACE
9 sleep apnea 32.3 REN NPPB EDN1 ACE
10 atrial standstill 1 32.2 TTN NPPB NPPA MYH7 MYH6 CRYAB
11 central sleep apnea 32.2 REN NPPB NPPA ACE
12 myocarditis 32.2 NPPB NPPA MYH6 ACE
13 tricuspid valve insufficiency 32.1 NPPB EDN1 ACE
14 arteries, anomalies of 32.1 REN NPPB EDN1 AGTR1 ACE
15 angina pectoris 32.1 NPPB EDN1 ADRB1 ACE
16 heart septal defect 32.1 NPPA MYH7 MYH6
17 systolic heart failure 32.0 NPPB NPPA EDN1 ADRB1 ACE
18 cardiogenic shock 32.0 NPPB ADM
19 heart valve disease 32.0 REN NPPB NPPA MYH7 MYH6 EDN1
20 atrial fibrillation 31.9 TTN REN NPPB NPPA MYH7 CACNA1C
21 mitral valve disease 31.9 REN NPPB NPPA AGTR1 ACE
22 coronary artery anomaly 31.9 VCL NPPB NPPA MYH6 EDN1 AGTR1
23 aortic valve insufficiency 31.9 REN NPPB ACE
24 mitral valve stenosis 31.9 REN NPPB NPPA ACE
25 pure autonomic failure 31.8 REN NPPA ACE
26 pericardial effusion 31.8 REN NPPB NPPA ACE
27 chronic kidney disease 31.8 REN NPPB NPPA EDN1 AGTR1 ADM
28 pulmonary hypertension 31.8 REN NPPC NPPB NPPA EDN1 AGTR1
29 diastolic heart failure 31.7 TTN REN NPPB NPPA AGTR1 ACE
30 pulmonary embolism 31.7 NPPB NPPA ACE
31 kidney disease 31.7 REN NPPC NPPB NPPA EDN1 AGTR1
32 end stage renal failure 31.7 REN NPPB NPPA AGTR1 ACE
33 syncope 31.7 TTN NPPA ACTN2
34 hypertrophic cardiomyopathy 31.6 VCL TTN MYH7 MYH6 EDN1 CRYAB
35 atrioventricular block 31.6 TTN NPPB MYH7 CRYAB CACNA1C ACE
36 dilated cardiomyopathy 31.6 VCL TTN REN NPPC NPPB NPPA
37 patent ductus arteriosus 1 31.6 NPPB MYH6 EDN1 ACE
38 right bundle branch block 31.6 NPPB CACNA1C ACE
39 constrictive pericarditis 31.5 TTN NPPB ACE
40 respiratory failure 31.5 TTN REN NPPB NPPA MYH7 EDN1
41 atrial heart septal defect 31.5 TTN NPPB NPPA MYH7 MYH6 EDN1
42 chagas disease 31.5 NPPB ADRB1 ACE
43 sleep disorder 31.5 REN EDN1 ACE
44 sick sinus syndrome 31.4 TTN NPPA MYH6 CACNA1C
45 anterolateral myocardial infarction 31.4 NPPB NPPA ACE
46 muscular dystrophy 31.4 VCL TTN MYH7 CRYAB ACTN2 ACE
47 sexual disorder 31.4 EDN1 ADRB1 ADRA2C ACE
48 impotence 31.3 EDN1 ADRA2C ACE
49 aortic valve disease 2 31.3 TTN REN NPPB NPPA MYH7 MYH6
50 cardiac tamponade 31.3 REN NPPB ACE

Graphical network of the top 20 diseases related to Congestive Heart Failure:



Diseases related to Congestive Heart Failure

Symptoms & Phenotypes for Congestive Heart Failure

UMLS symptoms related to Congestive Heart Failure:


tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

MGI Mouse Phenotypes related to Congestive Heart Failure:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
2 homeostasis/metabolism MP:0005376 10 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
3 mortality/aging MP:0010768 9.77 ACE ADM ADRA2C ADRB1 AGTR1 CACNA1C
4 muscle MP:0005369 9.36 ADM ADRB1 CACNA1C CRYAB EDN1 MYH6

Drugs & Therapeutics for Congestive Heart Failure

Drugs for Congestive Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 986)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
2
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
3
Etanercept Approved, Investigational Phase 4 185243-69-0
4
Insulin lispro Approved Phase 4 133107-64-9
5
Deferiprone Approved Phase 4 30652-11-0 2972
6
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
7
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
8
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
9
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
10 Iron protein succinylate Approved, Investigational Phase 4 250705-13-6
11
Zopiclone Approved Phase 4 43200-80-2 5735
12
Tirofiban Approved Phase 4 144494-65-5 60947
13
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
14
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
15
Pancrelipase Approved, Investigational Phase 4 53608-75-6
16
Cefazolin Approved Phase 4 25953-19-9 656510 33255
17
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
18
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
19
Glyburide Approved Phase 4 10238-21-8 3488
20
Pantoprazole Approved Phase 4 102625-70-7 4679
21
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
22
Ramipril Approved Phase 4 87333-19-5 5362129
23
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
24
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
25
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
26
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
27
Fenofibrate Approved Phase 4 49562-28-9 3339
28
Manidipine Approved, Investigational Phase 4 89226-50-6
29
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
30
Doxazosin Approved Phase 4 74191-85-8 3157
31
Desflurane Approved Phase 4 57041-67-5 42113
32
Magnesium citrate Approved Phase 4 3344-18-1
33 Apricot Approved Phase 4
34
Ibuprofen Approved Phase 4 15687-27-1 3672
35
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
36
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
37
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
38
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
39
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
40
Trandolapril Approved Phase 4 87679-37-6 5484727
41
Magnesium oxide Approved Phase 4 1309-48-4 14792
42
Terbutaline Approved Phase 4 23031-25-6 5403
43
Ledipasvir Approved Phase 4 1256388-51-8 67505836
44
Clevidipine Approved, Investigational Phase 4 167221-71-8
45
Dipyridamole Approved Phase 4 58-32-2 3108
46
Haloperidol Approved Phase 4 52-86-8 3559
47
Clozapine Approved Phase 4 5786-21-0 2818
48
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
49
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
50
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767

Interventional clinical trials:

(show top 50) (show all 6523)
# Name Status NCT ID Phase Drugs
1 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
2 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
3 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
4 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
5 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
6 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
7 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
8 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
9 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
10 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
11 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
12 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
13 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
14 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
15 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
16 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
17 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
18 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
19 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
20 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
21 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
22 Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications Unknown status NCT01682291 Phase 4
23 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
24 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
25 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
26 Impact of Lipophilic Versus Hydrophilic Statin Administration on The Clinical Outcome and Cardiac Markers of Patients With Heart Failure Unknown status NCT03255044 Phase 4 Atorvastatin;Rosuvastatin
27 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
28 Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
29 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
30 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
31 Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy Unknown status NCT03380520 Phase 4 Ferric Carboxymaltose;Placebo
32 A Pilot Feasibility Study in Recovered Heart Failure Unknown status NCT02859311 Phase 4 Withdrawal of therapy
33 Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure Unknown status NCT00988806 Phase 4 Levosimendan;Placebo
34 Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure Unknown status NCT00937092 Phase 4 Furosemide;low-dose dopamine + low-dose furosemide
35 The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial Unknown status NCT01942109 Phase 4 Furosemide;Torasemide
36 Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients Unknown status NCT02546856 Phase 4
37 Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence Unknown status NCT01016431 Phase 4
38 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
39 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
40 A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects. Unknown status NCT00885651 Phase 4 Metoprolole (Selo-Zok ®);Placebo
41 Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor Unknown status NCT01156207 Phase 4 Aliskiren
42 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
43 Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study Unknown status NCT03209180 Phase 4 CarVeDilol-SR (Slow Release);Carvedilol IR (Immediate Release)
44 Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function Unknown status NCT00418119 Phase 4 erythropoietin
45 Latin America Cardiac Resynchronization Therapy Study Unknown status NCT01238874 Phase 4
46 Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy Unknown status NCT02166060 Phase 4 Ivabradine
47 Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis Unknown status NCT02754518 Phase 4 Entresto
48 Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic Unknown status NCT01930734 Phase 4 Dobutamine;Normal Saline
49 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
50 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated Heart Failure Patients With Obstructive Sleep Apnea: A Two Center Pilot Study Unknown status NCT02963597 Phase 4

Search NIH Clinical Center for Congestive Heart Failure

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atenolol
benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Captopril
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
coenzyme Q10
cyclothiazide
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam
Fenoldopam Mesylate
Fosinopril
Fosinopril Sodium
Furosemide
Growth Hormone
Hydralazine
Hydralazine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Inamrinone
inamrinone lactate
Indapamide
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol
Labetalol hydrochloride
Lisinopril
Losartan
Losartan Potassium
Methyclothiazide
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Milrinone
Milrinone Lactate
moexipril
Moexipril hydrochloride
Nadolol
Nitroglycerin
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
Polythiazide
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Sodium Nitroprusside
somatrem
Somatropin
SOMATROPIN (RECOMBINANT DNA ORIGIN)
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Trichlormethiazide
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Congestive Heart Failure cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Congestive Heart Failure:
BMAC, autologous bone marrow aspirate concentrate for congestive heart failure
CD34+ stem cells for treatment of congestive heart failure
ERCs, endometrial regenerative cells for congestive heart failure
Peripheral or bone marrow-derived stem cells for chronic heart failure
C-Cure, mesenchymal stem cell-derived cardiomyocytes for heart failure
CD133+ bone marrow-derived stem cells in conjuction with coronary artery bypass grafting
Adipose-derived stem cells for treatment of congestive heart failure
Cardiac progenitor cells for single-ventricle anomalies
Mesenchymal precursor cells for cardiovascular diseases
Human cardiac-derived stem cell for the treatment of congestive heart failure
ACP-01, autologous angiogenic precursor cells for cardiac diseases
Enriched bone marrow-derived progenitor cells for heart diseases
Cardiosphere-derived autologous stem cells for reverse ventricular dysfunction
MyoCell, muscle stem cells for severe heart damage
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Bone marrow-derived adult mononuclear cells for heart diseases
Embryonic/Adult Cultured Cells Related to Congestive Heart Failure:
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 18351022 23788089 15995108
Bone marrow-derived mononuclear cells PMIDs: 20524773 20445812 19699857 22137069
Cardiac stem cells PMIDs: 17502484 14530411 18754813
Cardiac progenitor cells PMIDs: 17502484 14530411 18754813
Cardiosphere-derived cells PMIDs: 22336189
Cardiomyocyte-like cells PMIDs: 18835562 23583247
Bone marrow-derived CD133+ cells PMIDs: 17320570
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22163120
Bone marrow-derived progenitor cells PMIDs: 16990385 22651868 16990384 18794392 22936827 23362308
Endometrial regenerative cells PMIDs: 18005405 23510656 20398245 19232091
Human cardiac stem cells PMIDs: 17502484 19038683 17150190
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 20850099 21155976
Skeletal myoblasts (MyoCell) PMIDs: 19051139 15615560 16446778
Bone marrow-derived mononuclear cells PMIDs: 20668107 19761394 22834565 21596713
Angiogenic cell precursors
Adipose-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: heart failure

Genetic Tests for Congestive Heart Failure

Genetic tests related to Congestive Heart Failure:

# Genetic test Affiliating Genes
1 Congestive Heart Failure 29

Anatomical Context for Congestive Heart Failure

MalaCards organs/tissues related to Congestive Heart Failure:

40
Heart, Kidney, Lung, Testes, Endothelial, Bone, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Congestive Heart Failure:
# Tissue Anatomical CompartmentCell Relevance
1 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
2 Lateral Plate Mesoderm Splanchnic Mesoderm Pericytes Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Congestive Heart Failure

Articles related to Congestive Heart Failure:

(show top 50) (show all 55963)
# Title Authors PMID Year
1
Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol. 54 61
20128603 2010
2
Provider adherence to clinical guidelines related to lipid-lowering medications. 54 61
20180482 2010
3
Effects of eythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. 54 61
18760492 2010
4
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. 54 61
19763821 2010
5
Alterations in plasma semicarbazide-sensitive amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction. 54 61
20391898 2010
6
Crystal structure of the sodium-potassium pump (Na+,K+-ATPase) with bound potassium and ouabain. 54 61
19666591 2009
7
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 54 61
19560695 2009
8
The clinical pharmacology of eplerenone. 54 61
19379127 2009
9
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. 54 61
19327624 2009
10
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. 54 61
19269262 2009
11
[The cardiorenal syndrome and optimal treatment of renal anemia]. 54 61
19370853 2009
12
Brain natriuretic peptide (BNP) level is closely related to the extent of left ventricular sympathetic overactivity in chronic ischemic heart failure. 54 61
19293536 2009
13
Porous silicon affinity chips for biomarker detection by MALDI-TOF-MS. 54 61
18948066 2008
14
Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. 54 61
17662495 2008
15
Effect of erythropoietin in a patient with severe congestive heart failure--a case report. 54 61
18756924 2008
16
[Serum levels of fatty acid-binding protein and brain natriuretic peptide in children with pneumonia complicated by acute congestive heart failure]. 54 61
18554454 2008
17
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. 54 61
18458262 2008
18
A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. 54 61
18021271 2008
19
Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. 54 61
18219303 2008
20
Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure. 54 61
19804290 2008
21
B-type natriuretic peptide: a biomarker for the diagnosis and risk stratification of patients with septic shock. 54 61
18347270 2008
22
Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. 54 61
18446719 2008
23
Accuracy of the isovolumic relaxation time in the emergency diagnosis of new-onset congestive heart failure with preserved left ventricular systolic function in the setting of B-type natriuretic peptide levels in the mid-range. 54 61
17395301 2008
24
Clinical correlates of very high brain natriuretic peptide levels in hospitalized patients. 54 61
18256556 2008
25
The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. 54 61
19128227 2008
26
[The role of urotensin II in human pathophysiology]. 54 61
19323069 2008
27
The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. 54 61
18953278 2008
28
Low plasma levels of brain natriuretic peptide in severe acute heart failure: merely a case? 54 61
17382416 2007
29
Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure. 54 61
17967592 2007
30
The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. 54 61
17923351 2007
31
Aldosterone and end-organ damage. 54 61
17683282 2007
32
ANP is cleared much faster than BNP in patients with congestive heart failure. 54 61
17479256 2007
33
Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. 54 61
17223209 2007
34
AMPD1 gene polymorphism and survival in patients with stable congestive heart failure. 54 61
17452134 2007
35
Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean patients visiting emergency departments. 54 61
17452702 2007
36
Usefulness of bedside tissue Doppler echocardiography and B-type natriuretic peptide (BNP) in differentiating congestive heart failure from noncardiac cause of acute dyspnea in elderly patients with a normal left ventricular ejection fraction and permanent, nonvalvular atrial fibrillation: insights from a prospective, monocenter study. 54 61
17456069 2007
37
Evidence for coexistence of three beta-adrenoceptor subtypes in human peripheral lymphocytes. 54 61
17361123 2007
38
The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure. A study on 686 consecutive patients. 54 61
17452135 2007
39
Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. 54 61
17083971 2007
40
Plasma levels of adrenomedullin and atrial natriuretic peptide in patients with congestive heart failure of various etiologies. 54 61
17511350 2007
41
Discovery of new cardiovascular hormones for the treatment of congestive heart failure. 54 61
17346128 2007
42
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 54 61
17345160 2007
43
Gene polymorphism of angiotensin-converting enzyme and angiotensin II type 1 receptor in patients with congestive heart failure. 54 61
18767410 2007
44
Brain natriuretic peptide plasma level is a reliable indicator of advanced diastolic dysfunction in patients with chronic heart failure. 54 61
16476572 2007
45
Brain natriuretic peptide--the biological marker in the diagnosis of overt congestive heart failure and myocardial ischemia. 54 61
17694799 2007
46
Aquaporins as targets for drug discovery. 54 61
17692010 2007
47
Analytical and clinical performance of three natriuretic peptide tests in the emergency room. 54 61
17484634 2007
48
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. 54 61
16870827 2007
49
[Genetic polymorphism of beta-adrenergic receptors and mortality in ischemic heart disease]. 54 61
17374341 2007
50
[Plasma urotensin II level in patients with chronic congestive heart failure]. 54 61
18634521 2006

Variations for Congestive Heart Failure

ClinVar genetic disease variations for Congestive Heart Failure:

6 (show all 18) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABCC8 NM_001287174.2(ABCC8):c.3520G>A (p.Val1174Met)SNV Likely pathogenic 35609 rs141322087 11:17426099-17426099 11:17404552-17404552
2 ABCC8 NM_001287174.2(ABCC8):c.1793G>A (p.Arg598Gln)SNV Likely pathogenic 523361 rs1344172059 11:17452385-17452385 11:17430838-17430838
3 CACNA1C NM_000719.7(CACNA1C):c.3049-10C>TSNV Conflicting interpretations of pathogenicity 166769 rs186741807 12:2714835-2714835 12:2605669-2605669
4 ANK2 NM_001148.6(ANK2):c.10693G>A (p.Glu3565Lys)SNV Conflicting interpretations of pathogenicity 190573 rs786205727 4:114281990-114281990 4:113360834-113360834
5 MYH6 NM_002471.3(MYH6):c.3988G>A (p.Ala1330Thr)SNV Conflicting interpretations of pathogenicity 191714 rs757840030 14:23858255-23858255 14:23389046-23389046
6 CRYAB NM_001289808.2(CRYAB):c.460G>A (p.Gly154Ser)SNV Conflicting interpretations of pathogenicity 41926 rs150516929 11:111779556-111779556 11:111908832-111908832
7 TTN NM_001267550.2(TTN):c.63023C>T (p.Thr21008Ile)SNV Conflicting interpretations of pathogenicity 47188 rs72646850 2:179453429-179453429 2:178588702-178588702
8 TTN NM_001267550.2(TTN):c.69130C>T (p.Pro23044Ser)SNV Conflicting interpretations of pathogenicity 47265 rs55980498 2:179441932-179441932 2:178577205-178577205
9 TTN NM_001267550.2(TTN):c.84923A>C (p.Gln28308Pro)SNV Conflicting interpretations of pathogenicity 47441 rs201674674 2:179425936-179425936 2:178561209-178561209
10 TTN NM_001267550.2(TTN):c.8902+14T>ASNV Conflicting interpretations of pathogenicity 137827 rs13388274 2:179634392-179634392 2:178769665-178769665
11 ANK2 NM_001148.6(ANK2):c.4123-13T>CSNV Conflicting interpretations of pathogenicity 347321 rs759465783 4:114264160-114264160 4:113343004-113343004
12 EYA4 NM_004100.5(EYA4):c.347C>T (p.Ala116Val)SNV Conflicting interpretations of pathogenicity 355443 rs747223436 6:133777763-133777763 6:133456625-133456625
13 RYR2 NM_001035.3(RYR2):c.10640C>T (p.Thr3547Met)SNV Uncertain significance 201305 rs552050895 1:237886513-237886513 1:237723213-237723213
14 PRKAG2 NM_016203.4(PRKAG2):c.431C>T (p.Pro144Leu)SNV Uncertain significance 181485 rs150140412 7:151478273-151478273 7:151781187-151781187
15 VCL NM_014000.2(VCL):c.1490T>C (p.Ile497Thr)SNV Uncertain significance 505024 rs572757800 10:75854166-75854166 10:74094408-74094408
16 ACTN2 NM_001103.3(ACTN2):c.1727T>C (p.Met576Thr)SNV Likely benign 691721 1:236914840-236914840 1:236751540-236751540
17 TTN NM_001267550.2(TTN):c.23363C>T (p.Ser7788Phe)SNV Likely benign 691754 2:179585126-179585126 2:178720399-178720399
18 HCN4 NM_005477.3(HCN4):c.1243G>A (p.Val415Met)SNV Benign 412788 rs201978086 15:73624600-73624600 15:73332259-73332259

Expression for Congestive Heart Failure

Search GEO for disease gene expression data for Congestive Heart Failure.

Pathways for Congestive Heart Failure

Pathways related to Congestive Heart Failure according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.64 VCL TTN NPPC NPPA MYH6 CACNA1C
2
Show member pathways
12.37 VCL MYH7 MYH6 ACTN2
3
Show member pathways
12.26 NPPC NPPB NPPA EDN1 CACNA1C AGTR1
4
Show member pathways
12.11 NPPC NPPB NPPA MYH7 MYH6 CACNA1C
5 12.07 NPPA EDN1 CACNA1C ADRB1
6
Show member pathways
11.97 TTN MYH7 MYH6 EDN1 CACNA1C ADRB1
7 11.61 MYH7 MYH6 CACNA1C
8
Show member pathways
11.56 REN AGTR1 ACE
9 11.49 TTN MYH6 ACTN2
10 11.01 REN NPPA EDN1 CACNA1C AGTR1 ADRB1
11 10.98 CACNA1C ADRB1 ADRA2C ADM
12 10.92 NPPB NPPA MYH7

GO Terms for Congestive Heart Failure

Cellular components related to Congestive Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.1 VCL TTN REN NPPB NPPA MYH7
2 extracellular region GO:0005576 9.85 VCL TTN REN NPPC NPPB NPPA
3 muscle myosin complex GO:0005859 9.32 MYH7 MYH6
4 sarcomere GO:0030017 9.26 TTN MYH7 MYH6 ACTN2
5 Z disc GO:0030018 9.1 TTN MYH7 MYH6 CRYAB CACNA1C ACTN2

Biological processes related to Congestive Heart Failure according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.95 EDN1 CRYAB CDKN2B-AS1 ACE
2 protein folding GO:0006457 9.88 NPPC NPPB NPPA CRYAB
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.87 EDN1 CACNA1C AGTR1 ADM
4 female pregnancy GO:0007565 9.8 NPPA ADRA2C ADM
5 response to hypoxia GO:0001666 9.8 NPPC NPPA EDN1 CRYAB ADM
6 cardiac muscle contraction GO:0060048 9.75 TTN MYH7 MYH6
7 sarcomere organization GO:0045214 9.72 TTN MYH6 ACTN2
8 cGMP-mediated signaling GO:0019934 9.7 NPPC NPPB NPPA
9 positive regulation of heart rate GO:0010460 9.69 NPPA EDN1 ADM
10 regulation of blood vessel diameter GO:0097746 9.67 NPPB AGTR1 ACE
11 response to muscle stretch GO:0035994 9.65 NPPA EDN1
12 amyloid-beta metabolic process GO:0050435 9.65 REN ACE
13 regulation of the force of heart contraction GO:0002026 9.65 MYH7 MYH6 ADM
14 positive regulation of renal sodium excretion GO:0035815 9.64 NPPB EDN1
15 positive regulation of urine volume GO:0035810 9.64 NPPB EDN1
16 adult heart development GO:0007512 9.63 MYH7 MYH6
17 striated muscle contraction GO:0006941 9.63 TTN MYH7 MYH6
18 negative regulation of systemic arterial blood pressure GO:0003085 9.62 NPPB NPPA
19 cardiac muscle fiber development GO:0048739 9.62 TTN MYH6
20 angiotensin maturation GO:0002003 9.61 REN ACE
21 body fluid secretion GO:0007589 9.61 NPPB EDN1
22 cardiac muscle hypertrophy in response to stress GO:0014898 9.61 NPPA MYH7 MYH6
23 positive regulation of cGMP-mediated signaling GO:0010753 9.6 NPPC NPPA
24 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.59 AGTR1 ACE
25 renin-angiotensin regulation of aldosterone production GO:0002018 9.56 REN AGTR1
26 muscle filament sliding GO:0030049 9.56 TTN MYH7 MYH6 ACTN2
27 phospholipase C-activating angiotensin-activated signaling pathway GO:0086097 9.54 AGTR1 ACTN2
28 cGMP biosynthetic process GO:0006182 9.54 NPPC NPPB NPPA
29 receptor guanylyl cyclase signaling pathway GO:0007168 9.5 NPPC NPPB NPPA
30 regulation of vasoconstriction GO:0019229 9.46 EDN1 AGTR1 ADRA2C ACE
31 muscle contraction GO:0006936 9.43 VCL TTN MYH7 MYH6 CRYAB ACTN2
32 regulation of blood pressure GO:0008217 9.1 REN NPPB NPPA MYH6 EDN1 ACE

Molecular functions related to Congestive Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.71 TTN MYH7 MYH6 CACNA1C
2 actin filament binding GO:0051015 9.65 VCL TTN MYH7 MYH6 ACTN2
3 signaling receptor binding GO:0005102 9.63 REN NPPC NPPB NPPA EDN1 ADM
4 actin-dependent ATPase activity GO:0030898 9.46 MYH7 MYH6
5 epinephrine binding GO:0051379 9.43 ADRB1 ADRA2C
6 alpha-2A adrenergic receptor binding GO:0031694 9.37 ADRB1 ADRA2C
7 hormone activity GO:0005179 9.35 NPPC NPPB NPPA EDN1 ADM
8 bradykinin receptor binding GO:0031711 9.32 AGTR1 ACE
9 hormone receptor binding GO:0051427 8.8 NPPC NPPB NPPA

Sources for Congestive Heart Failure

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29